KDR and idiopathic pulmonary fibrosis: Nintedanib is a tyrosine kinase inhibitor, and its success in IPF has been attributed to the inhibition of several tyrosine kinase receptors, including the VEGFR, PDGFR, and FGFR (36, 38, 41).